NYBCe and Chan Zuckerberg Biohub Collaborate on iPSC Platform from Cord Blood
May 1, 2026 – 9:54 am
Summary:
The New York Blood Center Enterprises (NYBCe) and the Chan Zuckerberg Biohub are joining forces to create a library of induced pluripotent stem cell (iPSC) lines derived from cord blood. This initiative leverages NYBCe’s vast inventory of over 30,000 cord blood units—including rare HLA-homozygous donors—and Biohub’s expertise in reprogramming immune cells. The resulting iPSCs will serve as valuable shared resources for regenerative medicine, disease modeling, and cell therapy, addressing a critical gap between lab research and scalable treatments.
The Opportunity:
Most cord blood collected at birth is discarded, along with the potent stem cells it contains. This collaboration aims to change that by:
- Tapping into a Rich Resource: Using NYBCe’s extensive collection of cord blood, including rare genetic profiles.
- Leveraging Expertise: Applying Biohub’s advanced capabilities in reprogramming immune cells to create iPSCs with broad immunocompatibility.
- Facilitating Progress: Providing researchers with standardized, high-quality iPSC lines for diverse applications.
Addressing a Key Challenge:
The field of cell therapy has faced a significant bottleneck: translating promising laboratory results into scalable, safe, and effective treatments for patients. The collaboration between NYBCe and Biohub aims to bridge this gap by:
- Standardizing Production: Creating a library of iPSC lines that can be reliably produced and characterized.
- Improving Immunocompatibility: Ensuring the iPSCs are compatible with diverse human immune systems, reducing rejection risks in therapeutic applications.
- Accelerating Discovery: Providing researchers with readily accessible tools for disease modeling and drug discovery.
The iPSC Revolution:
Induced pluripotent stem cells hold immense potential across various medical fields:
- Neurodegenerative Diseases: Creating neurons for Parkinson’s and other neurodegenerative conditions.
- Cardiovascular Disease: Generating cardiomyocytes for heart failure therapies.
- Cancer: Producing immune cells for cancer immunotherapy.
Over 115 clinical trials involving pluripotent stem cell therapies are currently underway globally, with promising early results. The market for iPSCs is projected to grow significantly in the coming years.